Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This protein is the product of translational readthrough, where the ribosome bypasses a canonical stop codon to continue translating across adjacent open R\nreading frames of HAUS3 and POLN. Readthrough proteins can occur infrequently due to regulatory or sequence elements in mRNA[2][3][6]. Such fusion products may retain partial functions of their parental proteins—HAUS3 (a component involved in microtubule organization) and POLN (a specialized DNA polymerase involved in DNA repair)—but the specific structure, function, and physiological relevance of the HAUS3-POLN readthrough protein have not been established in the literature. There is no evidence for its therapeutic relevance or implications in human disease; its existence is annotated through bioinformatic prediction and ribosome profiling, not biochemical validation[2][6].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HAUS complex subunit 3–DNA polymerase nu readthrough protein (null).